Senhwa Biosciences Company Description

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents.

The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer.

It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma.

In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19.

Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.

Senhwa Biosciences, Inc.

Country	Taiwan
Founded	2012
Industry	Biotechnology
Sector	Healthcare
CEO	Jin-Ding Huang

Contact Details

Address: No. 225, Peihsin Road New Taipei City, 23143 Taiwan
Phone	886 2 8911 9856
Website	senhwabio.com

Stock Details

Ticker Symbol	6492
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006492002
SIC Code	2836

Key Executives

Name	Position
Jin-Ding Huang	Chief Executive Officer
Sarah Chang	Chief Financial Officer
Joanne Lo	Chief Operating Officer